Officials with the FDA have approved the first subcutaneous apomorphine infusion (Onapgo; Supernus) for patients with Parkinson’s disease (PD). Read More ›
Axsome Therapeutics, Inc., a biopharmaceutical company, has announced that the FDA has approved meloxicam and rizatriptan (Symbravo) for the acute treatment of migraine with or without aura in adults. Read More ›
Officials with Eisai Co., Ltd., and Biogen Inc. have announced the FDA nod for the supplemental biologics license application (sBLA) for once-every-4-weeks lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing. Read More ›
